Abstract
PD-1 blockade alone in heavily treated MSS/pMMR mCRC patients (pts) is ineffective. PD-1 blockade combined with antiangiogenic therapy has synergistic effects and has shown clinical benefits in several clinical trials. We aim to explore the efficacy and safety of TKIs combined with PD-1 blockade in TKI-responsive pts with MSS/pMMR mCRC refractory to standard chemotherapy (±anti-VEGF/EGFR).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
